Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this report, we found a rare case of RCC with a fusion between 5' EWSR1 and 3' TFE3.
|
31774608 |
2020 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ten patients with RBM10-TFE3 RCC aged 31-71 years were investigated.
|
30908700 |
2019 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The KAT6A-TFE3 renal cell carcinoma demonstrated typical morphological features of TFE3/Xp11 renal cell carcinoma including papillae, eosinophilic cytoplasm with focal clearing and abundant psammoma bodies.
|
30622287 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis was TFE3/Xp11.2 translocation RCC.
|
28478739 |
2019 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The TFE3-RCC mouse provides a preclinical <i>in vivo</i> model for the development of new biomarkers and targeted therapeutics for patients affected with this aggressive form of RCC.
|
31043488 |
2019 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
|
30849994 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To broaden the spectrum of Xp11 neoplasms, we investigated a novel tumor exhibiting morphologies overlapping Xp11.2 translocation/TFE3 rearrangement-associated RCC and the mesenchymal counterpart with melanocytic differentiation by immunohistochemistry, fluorescence in situ hybridization (FISH) and RNA sequencing, as well as literature review.
|
31277953 |
2019 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among the 27 renal cell carcinomas with TFE3 strong positive immunostaining, 20 cases were diagnosed as Xp11 translocation renal cell carcinoma, and seven cases were diagnosed as clear cell renal cell carcinoma.
|
31175325 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Magnetic resonance imaging findings of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in adults: a pilot study.
|
30019296 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Transcription factor E3 (TFE3) is a useful marker for tumors with Xp11.2 translocation, including alveolar soft part sarcoma and renal cell carcinoma.
|
31788112 |
2019 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dual mTORC1/2 inhibition suppresses Akt/mTOR signaling more effectively than selective mTORC1 inhibition and demonstrates in vivo preclinical efficacy against TFE3-fusion renal cell carcinoma.
|
31519159 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Xp11.2 translocation renal cell carcinoma (Xp11tRCC) is a subtype of renal cell carcinoma (RCC) characterized by chromosomal rearrangement of the region harboring the transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3).
|
31153695 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
|
30787990 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Two transcription factors in this family have been identified in two unusual types of renal cell carcinoma (RCC): Xp11 translocation RCC harbouring TFE3 gene fusions and t(6;11) RCC harbouring a MALAT1-TFEB gene fusion.
|
29148086 |
2018 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe a case of TFE3 translocation associated RCC in a 58-year-old patient, with emphasis on cytomorphologic features and clues toward this diagnostic entity.
|
29024535 |
2018 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Notably, 7/9 (78%) renal cell carcinomas exhibiting subnuclear clearing and linear nuclear array (6 of which showed high World Health Organization/International Society of Urological Pathology nucleolar grade) demonstrated TFE3 translocation, an association that was statistically significant when compared with renal cell carcinomas without MITF aberrations (P=0.009).
|
28840857 |
2018 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This is the first time to correlate the MED15-TFE3 renal cell carcinoma with specific clinicopathologic features.
|
29713041 |
2018 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
|
29890986 |
2018 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature.
|
29901594 |
2018 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We report a case of a 44-year-old man who has been treated with everolimus for a Xp11.2 translocation/TFE3 gene-fusion RCC after 2 previous failed treatments with tyrosine kinase inhibitor.
|
29702156 |
2018 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The TCGA data set of renal cell carcinoma was evaluated to validate TFE3 expression and survival analysis.
|
29968390 |
2018 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This report adds to the known data regarding NONO-TFE3 renal cell carcinoma.
|
27934879 |
2017 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic studies confirmed the diagnosis of Xp11.2 translocation-associated RCC with positive TFE3 gene rearrangement.
|
28877071 |
2017 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinomas (RCCs) with Xp11 translocation (Xp11 RCC) constitute a distinctive molecular subtype characterized by chromosomal translocations involving the Xp11.2 locus, resulting in gene fusions between the TFE3 transcription factor with a second gene (usually ASPSCR1, PRCC, NONO, or SFPQ).
|
28411178 |
2017 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These cases validate RBM10-TFE3 as a recurrent gene fusion in Xp11 translocation RCC, illustrate a source of false-negative TFE3 break-apart FISH, and highlight the complementary role of TFE3 IHC and TFE3 FISH.
|
28296677 |
2017 |